Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Dec;99(6):1580-1582.
doi: 10.4269/ajtmh.18-0387. Epub 2018 Sep 13.

Case Report: Subcutaneous Ivermectin Pharmacokinetics in Disseminated Strongyloides Infection: Plasma and Postmortem Analysis

Pamela Konecny  1   2 , Christopher J Weatherall  1   2 , Suman Adhikari  1   2 , Johan Duflou  3   4 , Veli Marjoniemi  1   2 , Carel J Pretorius  5   6 , Brett McWhinney  6
Affiliations
Case Reports

Case Report: Subcutaneous Ivermectin Pharmacokinetics in Disseminated Strongyloides Infection: Plasma and Postmortem Analysis

Pamela Konecny et al. Am J Trop Med Hyg. 2018 Dec.

Abstract

Parenteral ivermectin treatment of disseminated strongyloidiasis and hyperinfection is increasing, although not licensed in humans and with limited pharmacokinetic data available. Plasma and postmortem tissue analysis in an human immunodeficiency virus (HIV)/hepatitis C virus-positive man with disseminated strongyloidiasis suggests loading subcutaneous ivermectin doses are required, from which the central nervous system is protected.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
(A) Patient with ileostomy and purpuric macular abdominal rash characteristic of disseminated strongyloidiasis. (B) Ileal biopsy, magnification ×400, haematoxylin and eosin stain (H&E) stain demonstrating rhabtidiform Strongyloides larvae. This figure appears in color at www.ajtmh.org.
Figure 2.
Figure 2.
(A) Ivermectin treatment timeline demonstrating relationship between days of subcutaneous and nasogastric ivermectin doses, plasma ivermectin 1Ba concentration, and bronchial larval motility. (B) Postmortem tissue analysis of ivermectin 1Ba concentration.
See this image and copyright information in PMC

References

    1. Bisoffi Z, et al. 2013. Strongyloides stercoralis: a plea for action. PLoS Negl Trop Dis 7: e2214. - PMC - PubMed
    1. Puthiyakunnon S, Boddu S, Li Y, Zhou X, Wang C, Li J, Chen X, 2014. Strongyloidiasis—an insight into its global prevalence and management. PLoS Negl Trop Dis 8: e3018. - PMC - PubMed
    1. Mobley CM, Dhala A, Ghobrial RM, 2017. Strongyloides stercoralis in solid organ transplantation: early diagnosis gets the worm. Curr Opin Organ Transpl 22: 336–344. - PubMed
    1. Mejia R, Nutman T, 2012. Screening, prevention, and treatment for hyperinfection syndrome and disseminated infections caused by Strongyloides stercoralis. Curr Opin Infect Dis 25: 458–463. - PMC - PubMed
    1. Buonfrate D, Requena-Mendez A, Angheben A, Muñoz J, Gobbi F, Van Den Ende J, Bisoffi Z, 2013. Severe strongyloidiasis: a systematic review of case reports. BMC Infect Dis 13: 78–88. - PMC - PubMed

Publication types

MeSH terms